Table 1 Demographic and clinical features of the evaluated patients in retrospective phase.

From: The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational “real-life” study

 

Whole cohort, retrospective phase

Patients with atlantoaxial joint involvement, retrospective phase

Patients

717

15

Gender (female/male)

56.6%/43.4%

87.7%/13.3%

Age, mean ± SD, years

64.7 ± 12.3

58.0 ± 11.8

Disease duration at the first observation, median (range), years

10 (28)

6 (7)

 < 1 year

40.6%

40.0%

 Between 1 and 5 years

34.0%

33.3%

 Between 5 and 10 years

25.4%

26.7%

RF and/or ACPA

68.3%

100%

Extra-articular disease

6.7%

40.0%

Smoking habit

34.4%

46.6%

GCs low dose

78.2%

0.0%

GCs high dose

12.6%

100.0%

MTX

71.9%

100.0%

HCQ

25.9%

14.2%

LEF

13.1%

0.0%

SSZ

7.1%

0.0%

Biologic DMARDs

43.5%

60.0%

TNFis

26.2%

60.0%

Non-TNFis

17.3%

0.0%

Targeted synthetic DMARDs

2.5%

0.0%

  1. RF rheumatoid factor, ACPA anticitrullinated protein antibodies, GCs glucocorticoids, MTX methotrexate, HCQ hydroxychloroquine, LEF leflunomide, SSZ sulfasalazine, DMARD disease-modifying anti-rheumatic drug, TNFis tumor necrosis factor.
Back to article page